Eric Wikler, DO
Family Medicine · Henderson, NVNPI 1992889364
Payments from drug & device makers
Across 186 payments — averaging $17.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$509
- Boehringer Ingelheim$350
- Novo Nordisk$309
- Astellas Pharma US Inc$266
- Lilly USA, LLC$210
- Novartis$204
- plus $1K from 29 others
What the payments were for
- Food & beverage$3,22498%
- Education$652%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 26 | $509 |
| Boehringer Ingelheim | 20 | $350 |
| Novo Nordisk | 17 | $309 |
| Astellas Pharma US Inc | 11 | $266 |
| Lilly USA, LLC | 14 | $210 |
| Novartis | 10 | $204 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $183 |
| Pfizer | 9 | $152 |
| Johnson & Johnson | 9 | $134 |
| GSK | 8 | $130 |
| AstraZeneca | 6 | $95 |
| Amgen | 4 | $66 |
| Abbott | 2 | $57 |
| E.r. Squibb & Sons, L.L.C. | 3 | $57 |
| Bayer | 3 | $47 |
| Amarin Pharma, Inc. | 3 | $46 |
| Biohaven Pharmaceuticals, Inc. | 3 | $43 |
| Dexcom, Inc. | 2 | $42 |
| Hologic Sales And Service, LLC | 2 | $35 |
| Lundbeck LLC | 2 | $35 |
| Idorsia Pharmaceuticals US Inc | 2 | $34 |
| Esperion Therapeutics, Inc. | 2 | $34 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Exact Sciences | 2 | $29 |
| Vanda Pharmaceuticals Inc. | 2 | $26 |
| Gilead | 1 | $25 |
| Boston Scientific | 1 | $24 |
| Eisai Inc. | 1 | $19 |
| Lucid Diagnostics Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Braintree Laboratories, Inc. | 1 | $13 |
| Bardy Diagnostics, Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$3,289 in reported general payments places this provider in the 80th percentile of 902 family medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 253 | $252,518 |
| OzempicSemaglutide | 169 | $218,522 |
| MounjaroTirzepatide | 138 | $162,584 |
| JardianceEmpagliflozin | 132 | $144,293 |
| ProliaDenosumab | 54 | $93,658 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $65,165 |
| XareltoRivaroxaban | 62 | $64,005 |
| TrulicityDulaglutide | 36 | $55,983 |
| RybelsusSemaglutide | 27 | $43,283 |
| MyrbetriqMirabegron | 46 | $39,761 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $30,934 |
| FarxigaDapagliflozin Propanediol | 22 | $30,732 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $21,390 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 78 | $15,927 |
| LinzessLinaclotide | 28 | $14,773 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $309 | $261,805196 claims |
| PfizerEliquis, Paxlovid | $152 | $256,701301 claims |
| Lilly USA, LLCMounjaro, Trulicity | $210 | $218,567174 claims |
| Boehringer IngelheimJardiance | $350 | $144,293132 claims |
| AmgenProlia | $66 | $93,65854 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $130 | $80,11589 claims |
| Johnson & JohnsonXarelto | $134 | $64,00562 claims |
| Astellas Pharma US IncMyrbetriq | $266 | $39,76146 claims |
| AstraZenecaFarxiga | $95 | $30,73222 claims |
| AbbVieLinzess, Synthroid | $509 | $21,14691 claims |
| NovartisEntresto | $204 | $9,70613 claims |
| Sanofi-aventis U.S. LLCLantus | $15 | $5,13613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 902 family medicine providers in Nevada.
Other family medicine in Henderson
- Rita ChuangHenderson$476K
- Vincent MirkilHenderson$82K
- Ibrahim FakhouriHenderson$51K
- Badi EghterafiHenderson$38K
- Gautham ReddyHenderson$17K
- Yuan-Chung ChenHenderson$13K
- Travis HailstoneHenderson$8K
- Rogelio MachucaLas Vegas$3.3M
- Maxine InghamLas Vegas$2.9M
- Elliot ShinLas Vegas$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.